Status: Recruiting
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)
A non-comparative randomized phase 2 study, evaluating the efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for metastatic pancreatic ductal adenocarcinoma (PDAC), progressive after Gemcitabine-Abraxane or Gemcitabine monotherapy
Participants needed: 134
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Belgian Group of Digestive OncologyUpdated: Feb 6, 2025Locations: 13
Eligibility criteria
Histologically proven metastatic adenocarcinoma of the pancreas [+10]
Uncontrolled concurrent CNS, cardiac, infectious diseases, hypertension [+17]